A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer

To assess clinical utility of the 21-gene assay (Oncotype DX(®) Recurrence Score(®)), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Frazier, Thomas G., Fox, Kevin R., Smith, J. Stanley, Laronga, Christine, McSwain, Anita, Paul, Devchand, Schultz, Michael, Stilwill, Joseph, Teal, Christine, Weisberg, Tracey, Vacchino, Judith F., Sing, Amy P., Cherepanov, Dasha, Hsiao, Wendy, Chang, Eunice, Broder, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381203/
https://www.ncbi.nlm.nih.gov/pubmed/25789420
http://dx.doi.org/10.3390/ph8010107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381203/
https://www.ncbi.nlm.nih.gov/pubmed/25789420
http://dx.doi.org/10.3390/ph8010107

Ejemplares similares